Possible Role of Glucagon in Cyproheptadine-induced Increase of Insulin Secretion

Overview

Journal Acta Diabetol Lat

Specialty Endocrinology

Date 1982 Jul 1

PMID 6756004

Authors

A Pezzarossa

V Coiro

U BUTTURINI

Affiliations

Soon will be listed here.

Abstract

In order to test the hypothesis that insulin secretion may be affected by increased glucagon levels during cyproheptadine (CPH) administration, an arginine-glucose test was performed in 8 normal women and repeated after three days of CPH administration at a dose of 16 mg/day. Both the glucagon and the insulin response were increased by CPH treatment and so were their incremental areas. For glucagon, the increase was present at all times tested, for insulin this rise was significant only during the first 60 min of the arginine test and during the rapid secretory phase following glucose injection. The difference between the incremental areas of glucagon before and after CPH treatment was significantly correlated to the above mentioned insulin areas and to insulin peak values. These data are in agreement with the hypothesis that in vivo CPH action on insulin secretion may be partly mediated by its effects on circulating glucagon levels.

References

Marco J, Hedo J, Villanueva M . Inhibition of glucagon release by serotonin in mouse pancreatic islets. Diabetologia. 1977; 13(6):585-8. DOI: 10.1007/BF01236311. View

Feldman J, Quickel Jr K, Lebovitz H . Potentiation of insulin secretion in vitro by serotonin antagonists. Diabetes. 1972; 21(7):779-88. DOI: 10.2337/diab.21.7.779. View

Levin S, GRODSKY G, Hagura R, Smith D, FORSHAM P . Relationships between arginine and glucose in the induction of insulin secretion from the isolated, perfused rat pancreas. Endocrinology. 1972; 90(3):624-31. DOI: 10.1210/endo-90-3-624. View

Feldman J, Lebovitz H . Serotonin inhibition of in vitro insulin release from golden hamster pancreas. Endocrinology. 1970; 86(1):66-70. DOI: 10.1210/endo-86-1-66. View

Herbert V, Lau K, Gottlieb C, Bleicher S . Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab. 1965; 25(10):1375-84. DOI: 10.1210/jcem-25-10-1375. View

Joost H, Beckmann J, Holze S, Lenzen S, Poser W, HASSELBLATT A . Inhibition of insulin and glucagon release from the perfused rat pancreas by cyproheptadine (Periactinol, Nuran). Diabetologia. 1976; 12(3):201-6. DOI: 10.1007/BF00422086. View

Henquin J, Malvaux P, Lambert A . Glucagon immunoassay using polyethylene glycol to precipitate antibody-bound hormone. Diabetologia. 1974; 10(1):61-8. DOI: 10.1007/BF00421415. View

Lebovitz H, Feldman J . Pancreatic biogenic amines and insulin secretion in health and disease. Fed Proc. 1973; 32(7):1797-802. View

Efendic S, Cerasi E, Luft R . Arginine-induced insulin release in relation to the cyclic AMP system in man. J Clin Endocrinol Metab. 1972; 34(1):67-72. DOI: 10.1210/jcem-34-1-67. View

10.

Feldman J, Bivens C, Skyler J, Lebovitz H . Effect of cyproheptadine administration on insulin secretion in acromegalic, diabetic and normal subjects. Horm Metab Res. 1975; 7(4):279-83. DOI: 10.1055/s-0028-1093754. View

11.

Samols E, Marri G, Marks V . Interrelationship of glucagon, insulin and glucose. The insulinogenic effect of glucagon. Diabetes. 1966; 15(12):855-66. DOI: 10.2337/diab.15.12.855. View

12.

Pontiroli A, Micossi P, FOA P . Effects of serotonin, of its biosynthetic precursors and of the anti-serotonin agent metergoline on the release of glucagon and insulin from rat pancreas. Horm Metab Res. 1978; 10(3):200-3. DOI: 10.1055/s-0028-1093434. View

13.

Plonk J, Bivens C, Feldman J . Inhibition of hypoglycemia-induced cortisol secretion by the serotonin antagonist cyproheptadine. J Clin Endocrinol Metab. 1974; 38(5):836-40. DOI: 10.1210/jcem-38-5-836. View

14.

Marco J, Hedo J, Martinell J, Calle C, Villanueva M . Potentiation of glucagon secretion by serotonin antagonists in man. J Clin Endocrinol Metab. 1976; 42(2):215-21. DOI: 10.1210/jcem-42-2-215. View

15.

Efendic S, Cerasi E, Luft R . Role of glucose in arginine-induced insulin release in man. Metabolism. 1971; 20(6):568-79. DOI: 10.1016/0026-0495(71)90005-9. View

16.

Nakai Y, Imura H, Sakurai H, Kurahachi H, Yoshimi T . Effect of cyproheptadine on human growth hormone secretion. J Clin Endocrinol Metab. 1974; 38(3):446-9. DOI: 10.1210/jcem-38-3-446. View

17.

SHARP G . The adenylate cyclase-cyclic AMP system in islets of Langerhans and its role in the control of insulin release. Diabetologia. 1979; 16(5):287-96. DOI: 10.1007/BF01223617. View

18.

de Bold M, BENCOSME S . Effects of serotonin and its antagonists on the first phase of insulin release in normal and hypersomatotropic rats. Horm Metab Res. 1978; 10(6):500-5. DOI: 10.1055/s-0028-1093379. View

19.

Feldman J, Lebovitz H . Role of pancreatic monoamines in the impaired insulin secretion of the fasting state. Endocrinology. 1973; 92(5):1469-74. DOI: 10.1210/endo-92-5-1469. View

20.

Hintze K, Grow A, Fischer L . Cyproheptadine-induced alterations in rat insulin synthesis. Biochem Pharmacol. 1977; 26(21):2021-7. DOI: 10.1016/0006-2952(77)90011-9. View